Weijing Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weijing Yun has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Lei Qian
Advanced Institute for Medical Sciences Dalian Medical University Dalian China
2 shared publicationsRuqiang Yuan
Advanced Institute for Medical Sciences Dalian Medical University Dalian China
2 shared publicationsDongning Li
Dalian Municipal Women and Children's Medical Center (Group), Dalian, China
1 shared publicationErjiao Qiang
Department of Pathology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
1 shared publicationHu Xu
Wuhu Hospital and Health Science Center, East China Normal University, Shanghai 200241, China
1 shared publication- Hu Xu
Health Science Center, East China Normal University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 8 April 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103578
Hesperidin improves cardiac fibrosis induced by β-adrenergic activation through modulation of gut microbiota
- 8 April 2025
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (6) , 103578
Open AccessHesperidin improves cardiac fibrosis induced by β-adrenergic activation through modulation of gut microbiota
- Open Access
- 5 July 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 7 (4) , 397-407
Cucurbitacins mitigate vascular neointimal hyperplasia by suppressing cyclin A2 expression and inhibiting VSMC proliferation
Background: Restenosis frequently occurs after percutaneous angioplasty in patients with vascular occlusion and seriously threatens their health. Substantial evidence has revealed that preventing vascular smooth muscle cell proliferation using a drug‐eluting stent is an effective approach to improve restenosis. Cucurbitacins have been demonstrated to exert an anti‐proliferation effect in various tumors and a hypotensive effect. This study aims to investigate the role of cucurbitacins extracted from Cucumis melo L. (CuECs) and cucurbitacin B (CuB) on restenosis.Methods: C57BL/6 mice were subjected to left carotid artery ligation and subcutaneously injected with CuECs or CuB for 4 weeks. Hematoxylin–Eosin, immunofluorescence and immunohistochemistry staining were used to evaluate the effect of CuECs and CuB on neointimal hyperplasia. Western blot, real‐time PCR, flow cytometry analysis, EdU staining and cellular immunofluorescence assay were employed to measure the effects of CuECs and CuB on cell proliferation and the cell cycle in vitro. The potential interactions of CuECs with cyclin A2 were performed by molecular docking.Results: The results demonstrated that both CuECs and CuB exhibited significant inhibitory effects on neointimal hyperplasia and proliferation of vascular smooth muscle cells. Furthermore, CuECs and CuB mediated cell cycle arrest at the S phase. Autodocking analysis demonstrated that CuB, CuD, CuE and CuI had high binding energy for cyclin A2. Our study also showed that CuECs and CuB dramatically inhibited FBS‐induced cyclin A2 expression. Moreover, the expression of cyclin A2 in CuEC‐ and CuB‐treated neointima was downregulated.Conclusions: CuECs, especially CuB, exert an anti‐proliferation effect in VSMCs and may be potential drugs to prevent restenosis.
- 5 July 2024
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 7 (4) , 397-407
Open AccessCucurbitacins mitigate vascular neointimal hyperplasia by suppressing cyclin A2 expression and inhibiting VSMC proliferation
Background: Restenosis frequently occurs after percutaneous angioplasty in patients with vascular occlusion and seriously threatens their health. Substantial evidence has revealed that preventing vascular smooth muscle cell proliferation using a drug‐eluting stent is an effective approach to improve restenosis. Cucurbitacins have been demonstrated to exert an anti‐proliferation effect in various tumors and a hypotensive effect. This study aims to investigate the role of cucurbitacins extracted from Cucumis melo L. (CuECs) and cucurbitacin B (CuB) on restenosis.Methods: C57BL/6 mice were subjected to left carotid artery ligation and subcutaneously injected with CuECs or CuB for 4 weeks. Hematoxylin–Eosin, immunofluorescence and immunohistochemistry staining were used to evaluate the effect of CuECs and CuB on neointimal hyperplasia. Western blot, real‐time PCR, flow cytometry analysis, EdU staining and cellular immunofluorescence assay were employed to measure the effects of CuECs and CuB on cell proliferation and the cell cycle in vitro. The potential interactions of CuECs with cyclin A2 were performed by molecular docking.Results: The results demonstrated that both CuECs and CuB exhibited significant inhibitory effects on neointimal hyperplasia and proliferation of vascular smooth muscle cells. Furthermore, CuECs and CuB mediated cell cycle arrest at the S phase. Autodocking analysis demonstrated that CuB, CuD, CuE and CuI had high binding energy for cyclin A2. Our study also showed that CuECs and CuB dramatically inhibited FBS‐induced cyclin A2 expression. Moreover, the expression of cyclin A2 in CuEC‐ and CuB‐treated neointima was downregulated.Conclusions: CuECs, especially CuB, exert an anti‐proliferation effect in VSMCs and may be potential drugs to prevent restenosis.
- Open Access
- 8 December 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 170, 116000
Formononetin ameliorates isoproterenol induced cardiac fibrosis through improving mitochondrial dysfunction
- 8 December 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 170, 116000
Open AccessFormononetin ameliorates isoproterenol induced cardiac fibrosis through improving mitochondrial dysfunction